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Background 
Kearns-Sayre syndrome (KSS) is characterized by the onset of ophthalmoparesis and pigmentary 
retinopathy before age 20 years. Other frequently associated clinical features include cerebellar ataxia, 
cardiac conduction block, raised cerebrospinal fluid (CSF) protein content, and proximal myopathy. 
Affected children have short stature and often have multiple endocrinopathies including diabetes mellitus, 
hypoparathyroidism, and Addison disease. Renal tubular acidosis (proximal or distal) has been described 
in numerous cases, with occasional progression to end-stage renal failure. Bilateral sensorineural hearing 
loss is almost universal in those who survive into the fourth decade of life; this may not be fully corrected 
with hearing aids. 
Pathophysiology 
The mitochondrial genome is a 16569 base-pair closed circular loop of double-stranded DNA found in 
multiple copies within the mitochondrial matrix. The mitochondrial genome encodes the genetic information 
for the 13 polypeptide subunits essential for the process of oxidative phosphorylation. In addition, 
mitochondrial DNA (mtDNA) encodes 2 ribosomal RNA genes and 22 transfer RNA (tRNA) genes 
necessary for the intramitochondrial synthesis of these 13 polypeptides. The genome was first sequenced 
in its entirety in 1981,1 and this "Cambridge Sequence" was subject to minor revisions in 1999.2 The 
mitochondrial genome is remarkably concise, containing little noncoding capacity and no introns. mtDNA is 
inherited almost exclusively through the maternal lineage, with only a single report of paternal inheritance.3  
  
Located within the mitochondrial matrix, and lacking the efficient repair mechanisms available to nuclear 
DNA, mtDNA has a relatively high rate of mutation. Most of these mutations are inconsequential; however, 
a stable, replicative mutant mtDNA is sometimes produced. This is not necessarily a problem for the cell or 
tissue because multiple copies of mtDNA are present in each cell (in oocytes, this is in the region of 
100,000 copies per cell), and both wild type and mutated mtDNA can coexist, a situation known as 
heteroplasmy. Disease only ensues when the proportion of mutated to wild-type mtDNA exceeds a tissue-
specific threshold. This is usually in excess of 65% mutated mtDNA but can widely vary between tissues 
and individuals. Thus, the level of mutant heteroplasmy is an important determinant of the clinical 
presentation of mitochondrial disease; however, other factors, such as nuclear genetic background, must 
also be considered. 
 
Kearns Sayre Syndrome (OMIM #530000) occurs as a result of large-scale single deletions (or 
rearrangements) of mitochondrial DNA (mtDNA), which are usually not inherited but occur spontaneously, 
probably at the germ-cell level or very early in embryonic development.4 The risk of maternal transmission 
has been estimated to be approximately 1 in 24.5 The deletions vary in size and location on the 
mitochondrial genome in different individuals, although a common deletion of 4.9kB is present in at least a 
third of patients with Kearns-Sayre syndrome.  
How can a heterogeneous group of mitochondrial deletions lead to a similar phenotype? The proposed 
mechanism is based on the knowledge that transcription of mtDNA is polycistronic, which means that all 
genes encoded on the heavy and light strands are transcribed as 2 large precursor RNA strands. These 
subsequently cleave into separate RNA strands, including transfer RNA strands. A deletion anywhere in 
the mitochondrial genome may affect transcription or translation of genes that were not affected by the 
deletion. 
An identical deletion has been identified in patients with 2 other conditions: Pearson syndrome, which is a 
sideroblastic anemia of childhood, pancytopenia, and exocrine pancreatic failure, and chronic progressive 
external ophthalmoplegia (CPEO), which consists of external ophthalmoplegia, bilateral ptosis, and 
proximal myopathy. Mitochondrial deletions in CPEO tend to be localized in muscle tissue; in Pearson 
syndrome, mutations occur in hematopoietic cells, explaining the different clinical phenotypes. 
Neither size nor location of the deletion alone determines clinical phenotype. Instead, the phenotype 
appears to be determined by the relative amounts of deleted and wild-type mtDNA. Very high levels of 
deleted mtDNA in all tissues are likely to cause Pearson syndrome, in which the dominant feature is 
pancytopenia. Lower levels of deleted mtDNA cause Kearns-Sayre syndrome. In CPEO, deleted mtDNA 
may be detected only in muscle tissue. CPEO and Kearns-Sayre syndrome vary in the location and 
percentage of mtDNA deletion.6 Exceptions are recognized, and survivors of the pancytopenic crisis of 
Pearson syndrome can also develop Kearns-Sayre syndrome. 
Frequency 
International 
Kearns-Sayre syndrome is a rare disorder. Marked heterogeneity and various types of inheritance have 
been observed. By 1992, authors had described 226 cases. 
 
Two studies have provided congruent information on the prevalence of large-scale mitochondrial deletions 
in the adult population. Remes et al estimated a prevalence of 1.6 cases per 100,000 population in a 
Finnish population (6 patients, only 3 of whom fulfilled the clinical criteria for Kearns-Sayre syndrome).7 
Schaefer et al estimated a prevalence of 1.17 cases per 100,000 population of large-scale mitochondrial 
deletions in North East England; however, the proportion of patients with Kearns-Sayre syndrome is not 
stated.8  
Mortality/Morbidity 
Although Kearns-Sayre syndrome probably reduces life expectancy, no numerical data are available. 
Morbidity depends on severity and the number of systems or organs involved, which widely varies from 
patient to patient. Heart block is a significant and preventable cause of mortality. 
Race 
Kearns-Sayre syndrome has no known racial predilection. 
Sex 
Kearns-Sayre syndrome has no known sex predilection. 
Age 
Part of the characterization of Kearns-Sayre syndrome is onset in individuals younger than 20 years. 
Clinical 
History 
The following are noted in patients with Kearns-Sayre syndrome (KSS): 
• Muscle weakness  
o Chronic and progressive decreased eye movements and ptosis 
o Dysphagia 
o Skeletal muscle weakness (proximal more than distal) and exercise intolerance 
• CNS dysfunction  
o Ataxia 
o Dementia, encephalopathy, or specific focal neuropsychological deficits 
o Deafness 
o Night blindness 
• Cardiac disease  
o Syncope 
o Palpitations 
• Symptoms of endocrine dysfunction  
o Diabetes mellitus 
o Menstrual irregularities, delayed puberty 
o Poor growth, failure to thrive 
o Seizures due to hypocalcemia (hypoparathyroidism) 
Physical 
In patients with Kearns-Sayre syndrome, signs are as follows: 
• Muscle weakness  
o Proximal myopathy (difficulty rising from a squat) 
o Ptosis (usually bilateral but may be symmetrical initially) 
o External ophthalmoplegia (as is seen in the image below) 
o  
 
Bilateral ptosis and external ophthalmoplegia. Top: patient looking 
straight ahead. Below: patient is being asked to look in the direction of 
the arrow in each case. Restriction of eye movements in each direction 
is demonstrated. 
• CNS dysfunction  
o Retinitis pigmentosa 
o Cerebellar ataxia 
o Cognitive deficits9  
o Cataracts 
o Encephalopathy (in acute presentation with lactic acidosis) 
• Cardiac  
o Bradycardia 
o Congestive cardiac failure 
• Endocrine  
o Short stature (38% of affected individuals) 
o Hypogonadism (20% of affected individuals) 
o Other (eg, signs of hypothyroidism) 
Causes 
• Kearns-Sayre syndrome occurs secondary to deletions in mtDNA (see Pathophysiology). 
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